Kristie L. Kahl

Treatment with the KRAS G12C inhibitor adagrasib showed a promising objective response rate and disease control rate in patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The combination of nimotuzumab and gemcitabine extended overall survival in patients with KRAS wild-type advanced pancreatic cancer, especially in those who did not need surgery for obstruction of a pancreatic bile duct

Adding pembrolizumab to CG0070 led to a complete response rate of 88.9% among 18 patients in the phase 2 CORE1 trial.

According to new research, genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.

According to Matthew Galsky, MD, results from the CheckMate-274 clinical trial support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection.

Increased rates of complete responses with bone marrow undetectable minimal residual disease were seen with the time-limited combination of ibrutinib plus chemoimmunotherapy in younger fit patients with chronic lymphocytic leukemia.

Minimum residual disease can inform approaches to treatment of newly diagnosed multiple myeloma for patients receiving daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant.

Chemotherapy with the addition of eryaspase showed biological efficacy in reducing hypersensitivity reactions to asparaginase in patients with acute lymphoblastic leukemia.

Older patients with diffuse large B-cell lymphoma experienced improved progression-free survival, quality of life, and function after receiving ibrutinib plus rituximab and mini-CHOP.

Combining daratumumab with bortezomib, cyclophosphamide, and dexamethasone improved hematologic and organ responses after 18 months of follow-up in the phase 3 ANDROMEDA study.

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.

Among patients with malignant pheochromocytoma and paraganglioma, treatment with sunitinib demonstrated improved efficacy.

Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.

The combination regimen was well tolerated with promising preliminary anti-tumor activity in patients with heavily pretreated esophageal cancer, who had not received immunotherapy.

Treatment with avapritinib in Chinese patients with PDGFRA D842V-mutant gastrointestinal stromal tumors revealed promising clinical benefit, according to a bridging study of the NAVIGATOR trial.

Patients with unresectable hepatocellular carcinoma with Child-Pugh class B liver function experienced a similar tumor size reduction as their Child-Pugh class A counterparts, all treated with lenvatinib, according to a post-hoc analysis of the phase 3 REFLECT study.

Updated results from the phase 1/2 CARTITUDE-1 trial showed that responses to ciltacabtagene autoleucel were deep and durable in patients with relapsed or refractory multiple myeloma. Data at a median follow-up of 18 months were presented at the 2021 European Hematology Association Congress.

Following rituximab resistance, the combination of lenalidomide and rituximab led to durable improvements in outcome for patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas, even after 10 years of follow-up, according to long-term results presented at the European Hematology Association 2021 Congress.

Daratumumab added to the standard of care with lenalidomide and dexamethasone continued to show a survival benefit over Rd alone in patients with transplant-ineligible, newly diagnosed multiple myeloma after almost 5 years of follow-up, updated results from the phase 3 MAIA trial show.

According to updated results presented during the 2021 ASCO Annual Meeting, teclistamab administered at the recommended phase 2 dose demonstrated encouraging safety and efficacy among patients with relapsed/refractory multiple myeloma treated in a first-in-human phase 1 trial.

The risk of fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer was controlled by the use of bone-protecting agents during treatment with radium-223 plus enzalutamide.

A second-generation 4chimeric antigen receptor (CAR) T-cell agent has induced responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated in a phase 1 study.

Median duration of response was doubled with tivozanib compared with sorafenib in patients with metastatic renal cell carcinoma.

Long-term follow-up data from the KarMMa trial found that treatment with the chimeric antigen receptor T-cell therapy, idecabtagene vicleucel, continues to demonstrate improved survival among heavily pretreated patients with relapsed/refractory multiple myeloma.

In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.

Neoadjuvant nivolumab added to chemotherapy lead to an improvement in pathological complete responses, compared with chemotherapy alone, as treatment of patients with resectable non-small cell lung cancer.

No statistically significant difference was seen with the combination of olaparib and cediranib compared to cediranib alone in patients with recurrent, metastatic or persistent endometrial cancer.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.